Evidence map›Paper›PMID 34694731›Full record

ArticleIET nanobiotechnology2021

Graphene oxide-ellagic acid nanocomposite as effective anticancer and antimicrobial agent.

Samer Hasan Hussein-Al-Ali, Suha Mujahed Abudoleh, Mohd Zobir Hussein, Saifullah Bullo, Arul Palanisamy

Open access · goldAbstract read
In one paragraph

Article in IET nanobiotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Anti-microbial, anti-biofilm, and efflux pump inhibitory effects of ellagic acid-bonded magnetic nanoparticles against Escherichia coli isolates.International microbiology : the official journal of the Spanish Society for Microbiology · 2025
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Graphene Oxide Thin Films with Drug Delivery Function.Nanomaterials (Basel, Switzerland) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Samer Hasan Hussein-Al-AliDepartment of Chemistry, Faculty of Science, Isra University, Amman, Jordan.ORCID https://orcid.org/0000-0002-8760-6069
Suha Mujahed AbudolehFaculty of Pharmacy, Isra University, Amman, Jordan.
Mohd Zobir HusseinMaterials Synthesis and Characterization Laboratory, Institute of Advanced Technology (ITMA), University Putra Malaysia, Selangor, Malaysia.
Saifullah BulloMaterials Synthesis and Characterization Laboratory, Institute of Advanced Technology (ITMA), University Putra Malaysia, Selangor, Malaysia.
Arul PalanisamyLaboratory of Vaccines and Immunotherapeutics, Institute of Bioscience, University Putra Malaysia, Selangor, Malaysia.
Universiti Putra Malaysia · MYIsra University · JO

Funding

Isra UniversityUniversity Putra Malaysia 94431004
6 · The paper itself

Abstract

In this study, ellagic acid (ELA), a skin anticancer drug, is capped on the surface(s) of functionalised graphene oxide (GO) nano-sheets through electrostatic and π-π staking interactions. The prepared ELA-GO nanocomposite have been thoroughly characterised by using eight techniques: Fourier-transform infrared spectroscopy (FTIR), zeta potential, X-ray diffraction (XRD), thermogravimetric analysis (TGA), Raman spectroscopy, atomic force microscopy (AFM) topographic imaging, transmission electron microscopy (TEM), and surface morphology via scanning electron microscopy (SEM). Furthermore, ELA drug loading and release behaviours from ELA-GO nanocomposite were studied. The ELA-GO nanocomposite has a uniform size distribution averaging 88 nm and high drug loading capacity of 30 wt.%. The in vitro drug release behaviour of ELA from the nanocomposite was investigated by UV-Vis spectrometry at a wavelength of λ

Indexed as

Anti-Infective AgentsGraphiteNanocompositesEllagic AcidAnti-Infective AgentsEllagic Acidgraphene oxideGraphite

Identifiers

PMID34694731
PMCPMC8675783
OpenAlexW3128200296

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.